Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary.

Singh, S; Carnaghi, C; Buzzoni, R; Pommier, R; Raderer, M; Tomasek, J; Lahner, H; Valle, Juan W; Voi, M; Bubuteishvili-Pacaud, L; Lincy, J; Wolin, E; Okita, N; Libutti, S; Oh, D; Kulke, M; Strosberg, J; Yao, J; Pavel, M; Fazio, N

dc.contributor.author	Singh, S
dc.contributor.author	Carnaghi, C
dc.contributor.author	Buzzoni, R
dc.contributor.author	Pommier, R
dc.contributor.author	Raderer, M
dc.contributor.author	Tomasek, J
dc.contributor.author	Lahner, H
dc.contributor.author	Valle, Juan W
dc.contributor.author	Voi, M
dc.contributor.author	Bubuteishvili-Pacaud, L
dc.contributor.author	Lincy, J
dc.contributor.author	Wolin, E
dc.contributor.author	Okita, N
dc.contributor.author	Libutti, S
dc.contributor.author	Oh, D
dc.contributor.author	Kulke, M
dc.contributor.author	Strosberg, J
dc.contributor.author	Yao, J
dc.contributor.author	Pavel, M
dc.contributor.author	Fazio, N
dc.date.accessioned	2018-06-27T19:49:20Z
dc.date.available	2018-06-27T19:49:20Z
dc.date.issued	2018
dc.identifier.citation	Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. 2018, 106(3): 211-220 Neuroendocrinology	en
dc.identifier.issn	1423-0194
dc.identifier.pmid	28554173
dc.identifier.doi	10.1159/000477585
dc.identifier.uri	http://hdl.handle.net/10541/621051
dc.description.abstract	The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine tumors (NET). This analysis specifically evaluated NET patients with GI and unknown primary origin.
dc.language.iso	en	en
dc.rights	Archived with thanks to Neuroendocrinology	en
dc.title	Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary.	en
dc.type	Article	en
dc.contributor.department	Sunnybrook Health Sciences Centre, Toronto, ON	en
dc.identifier.journal	Neuroendocrinology	en
refterms.dateFOA	2020-04-27T11:19:44Z
html.description.abstract	The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine tumors (NET). This analysis specifically evaluated NET patients with GI and unknown primary origin.